Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Cognitive function, body composition and IGF-I SDS of PWS adolescents at different stages in the study

From: Effect of cessation of GH treatment on cognition during transition phase in Prader-Willi syndrome: results of a 2-year crossover GH trial

  Treatment schedule p-value
Placebo/GH (n = 12) GH/Placebo (n = 13)
After 1 year placebo After 1 year GH After 1 year GH After 1 year placebo
Total IQ 61 (55 to 69) 62 (58 to 69) 69 (60 to 73) 70 (57 to 80) 0.832
Verbal IQ 62 (55 to 66) 65 (57 to 70) 66 (57 to 75) 67 (55 to 76) 0.486
 - Vocabulary −2.3 (−2.7 to −2.0) −2.2 (−2.9 to −2.0) −2.3 (−3.0 to −1.3) −2.0 (−2.7 to −1.5) 0.650
 - Similarities −1.8 (−2.2 to −1.7) −1.7 (−2.3 to −1.1) −1.3 (−2.3 to −1.0) −1.3 (−2.3 to −1.0) 0.943
 - Arithmetic −2.0 (−2.2 to −2.0) −2.0 (−2.0 to −1.7) −2.0 (−2.0 to −1.7) −2.0 (−2.0 to −1.8) 0.320
 - Digit Span −2.2 (−2.8 to −1.7) −2.3 (−2.9 to −1.8) −2.0 (−2.3 to −1.8) −2.0 (−2.3 to −1.8) 0.793
 - Information −1.7 (−2.6 to −1.7) −1.8 (−2.0 to −1.4) −1.7 (−2.0 to −1.1) −1.8 (−2.3 to −1.3) 0.154
 - Comprehension −2.3 (−2.7 to −2.3) −2.2a (−2.6 to −2.0) −2.0 (−2.6 to −1.4) −2.0 (−2.6 to −1.4) 0.123
Performance IQ 59 (53 to 72) 57 (52 to 70) 67 (57 to 75) 69 (55 to 78) 0.322
 - Picture Completion −2.2 (−2.9 to −1.7) −2.5 (−2.9 to −1.7) −1.7 (−2.8 to −0.8) −1.3 (−2.3 to −0.4) 0.130
 - Coding −3.0 (−3.0 to −2.2) −2.7 (−3.0 to −2.3) −2.5 (−3.0 to −1.5) −2.3 (−3.0 to −1.5) 0.903
 - Block design −2.0 (−2.2 to −1.4) −1.5a (−2.0 to −1.3) −1.7 (−1.8 to −1.2) −1.7 (−2.0 to −1.0) 0.075
 - Matrix Reasoning −1.7 (−2.1 to −1.3) −2.3a (−2.3 to −1.7) −2.2 (−2.3 to −1.2) −2.2 (−2.3 to −1.3) 0.376
 - Picture Arrangement −2.3 (−2.6 to −1.2) −2.0 (−2.3 to −1.4) −1.7 (−1.7 to −1.0) −1.3 (−2.0 to −1.0) 0.611
FM% 45.3 (38.2 to 48.3) 41.7 (30.6 to 50.6) 39.3a (33.2 to 49.8) 44.1 (38.4 to 52.3) 0.002
Lean body mass (kg) 32.3 (30.6 to 45.1) 34.6a (31.6 to 44.0) 35.1 (32.6 to 41.3) 36.7 (31.5 to 39.2) 0.008
IGF-I SDS −0.4 (−0.9 to −0.3) 2.1a (0.0 to 2.4) 1.8a (1.5 to 2.4) −0.7 (−1.7 to 0.3) <0.001
  1. Data expressed in SDS; median with IQR. P-value of mean difference between placebo and GH administration, tested by Wilcoxon tests
  2. awithin Placebo/GH or GH/placebo group; significantly different compared to placebo